ERCP is the procedure most closely linked to the Olympus endoscope litigation. If you or a loved one suffered a serious infection after ERCP, you may qualify for a free case review.
Endoscopic Retrograde Cholangiopancreatography (ERCP) is a specialized procedure that combines endoscopy and fluoroscopic imaging to diagnose and treat conditions affecting the bile ducts, pancreatic duct, and gallbladder. ERCP is used to remove gallstones, place stents, take biopsies, and treat blockages in the biliary and pancreatic systems.
ERCP requires a duodenoscope—a side-viewing endoscope with an elevator mechanism that guides instruments into the bile and pancreatic ducts. This elevator mechanism is at the center of the Olympus endoscope lawsuit because its complex design makes thorough cleaning between patients extremely difficult. Even hospitals that follow all recommended reprocessing protocols have experienced contamination events.
Approximately 500,000 to 700,000 ERCP procedures are performed annually in the United States. While ERCP is a critical tool for treating biliary and pancreatic diseases, the procedure carries inherent risks that are amplified when the duodenoscope is contaminated.
Why ERCP carries the highest contamination risk
The duodenoscope's elevator mechanism is the primary contamination concern. This small mechanical component at the device's distal tip has recessed crevices that can trap blood, bile, tissue, and bacteria. Studies have shown that standard reprocessing may not eliminate all biological material from this area, allowing organisms to survive and be transmitted to the next patient.
The FDA has issued multiple safety communications about duodenoscope contamination risks during ERCP, beginning in 2015. Investigations at major medical centers have linked contaminated duodenoscopes to outbreaks of CRE (carbapenem-resistant Enterobacteriaceae), E. coli, and other serious infections. Some outbreaks affected dozens of patients at a single hospital.
ERCP patients are particularly vulnerable because the procedure involves accessing the bile and pancreatic ducts—areas that are normally sterile. Bacteria introduced through a contaminated duodenoscope can cause rapid, serious infections including cholangitis, pancreatitis, and sepsis.
Injuries associated with ERCP infections
Patients who develop infections after ERCP with a contaminated duodenoscope may suffer:
Cholangitis (bile duct infection) with fever, jaundice, and right upper quadrant pain
Acute pancreatitis triggered or worsened by contaminated instruments
CRE or other superbug infections resistant to most available antibiotics
Sepsis and septic shock requiring ICU admission and aggressive treatment
Bacteremia with E. coli, Klebsiella, or other Gram-negative organisms
Multi-organ failure in severe infection cases
Death from overwhelming sepsis or antibiotic-resistant infections
Legal claims in ERCP infection cases
ERCP infection lawsuits are at the core of the Olympus endoscope litigation. These claims typically allege that the duodenoscope's elevator mechanism design is defective because it creates contamination risks that cannot be eliminated through reprocessing, that Olympus failed to adequately warn about these risks, and that the company delayed safety actions despite evidence of patient harm.
Because ERCP infections have been the subject of FDA safety communications, congressional investigations, and peer-reviewed research, plaintiffs in ERCP cases often have strong supporting evidence. Internal Olympus documents obtained through discovery have further supported claims of corporate knowledge and delayed action.
Key evidence for ERCP infection claims
ERCP procedure report identifying the Olympus duodenoscope model (TJF-Q180V, TJF-Q190V, or TJF-Q290V)
Post-ERCP infection cultures showing CRE, ESBL-producing organisms, or other pathogens
Hospital notification letters about duodenoscope contamination or superbug exposure
ICU admission and treatment records following the infection
Discharge summaries and follow-up care documentation
Primary sources
When researching infection risk, reprocessing, or regulatory history, verify facts using official agency materials. Summaries on this site are for education and intake screening, not medical or legal advice.
Reprocessing reusable medical devices — U.S. Food and Drug Administration. FDA hub for flexible endoscope reprocessing requirements, labeling, and safety communications.
For overlapping questions about screening, timelines, and how Top Tier Legal connects inquiries with counsel, see the Olympus endoscope lawsuit FAQ on the main practice page rather than duplicating those answers on every procedure page.
If your situation involves an Olympus endoscope ercp (endoscopic retrograde cholangiopancreatography) procedure and a qualifying injury, start your free, confidential case review below.
Top Tier Legal, LLC is not a law firm and does not provide legal advice. Submitting information does not create an attorney-client relationship. If you qualify, we may connect you with an independent law firm.
